Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere to Underwrite up to Eight Research Projects at Mass General Brigham

publication date: Jun 13, 2023

Simcere Pharma signed a Sponsored Research Agreement with Mass General Brigham of Boston to discover new treatments for patients with cancer, autoimmune and CNS disease. Under the agreement, Simcere will fund up to eight research groups at Mass General Brigham on selected projects over the next two years. Simcere will have access to cutting-edge research and leading clinical skills, which will accelerate its global R&D efforts. In addition, Simcere’s Project X, which provides talented scientists with funding and employment, will further contribute to Boston’s local medical research community. More details....

Stock Symbol: (HK: 2096)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital